Targeting phospholipase A2 for the treatment of inflammatory skin disease

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1549-1552

  Burke, J R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cytokine production; Dermatitis; Inflammation; Phospholipase A2; Psoriasis

Indexed keywords

4 (3 CARBOXYPHENYL) 3,7 DIMETHYL 9 (2,6,6 TRIMETHYL 1 CYCLOHEXENYL) 2,4,6,8 NONATETRAENOIC ACID; ARACHIDIC ACID; BMS 188184; BMS 229724; GLUCOCORTICOID; IBUPROFEN; ICOSANOID; INDOMETACIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A1; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZILEUTON; ENZYME INHIBITOR; PHOSPHOLIPASE A;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME BINDING; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PSORIASIS; REVIEW; SKIN INFLAMMATION; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METHODOLOGY;

ANIMAL; DERMATITIS, ATOPIC; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMAN; PHOSPHOLIPASES A; PSORIASIS;

EID: 0034747079     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Determination of 5, 12, and 15-lipoxygenase products in keratomed biopsies of normal and psoriatic skin
2. 4 are present in biologically active concentrations
3. A pilot study examining the role of zileuton in atopic dermatitis
4. 2: Mediators of inflammation, proliferation and apoptosis
5. 2 in murine bone marrow-derived mast cells
6. Role of cytosolic phospholipase in allergic response and parturition
7. 2
8. 2
9. 2 with topical anti-inflammatory activity
10. 2 blocks eicosanoid and platelet activator factor biosynthesis and has topical anti-inflammatory activity
11. 2
12. 2 by the anti-inflammatory agent BMS-181162
13. Mouse skin inflammation induced by multiple topical applications of 12-O-tetracanoylphorbol-13-acetate
14. An update on inhibitors of human 14 kDa Type II sPLA2 in development
15. 2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models
16. Nuclear factor κB in activated by arachidonic acid but not by eicosapentaenoic acid
17. Role of cytosolic phospholipase A2 as a downstream mediator of rac in the signaling pathway to JNK stimulation
18. 2 modulates tumor necrosis factor-α- and interleukin-1β-induced NF-κB activation
19. Interleukin-1 receptor antagonist suppresses contact hypersensitivity
20. An essential role for Langerhans cell-derived IL-1β in the initiation of primary immune responses in skin
21. Quantification of chemotactic peptides (C5 anaphylatoxin and IL-8) in psoriatic lesional skin
22. Mechanisms of UV-induced inflammation
23. Effect of topical indomethacin on UVR-induced redness and PGE2 levels in sunburned guinea pig skin
24. 2 in human skin
25. 2 inhibitors in inflammation
26. Competitive, reversible inhibition of cytosolic phospholipase A2 at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer